Use of cotinine in treating psychiatric disorders

- LecTec Corporation

Methods are provided for treating schizophrenia, Tourette's Syndrome, obsessive-compulsive disorder, substance abuse or substance addiction including drug or alcohol addiction, manic-depression syndrome, anexoria or bulimia comprising administering an amount of cotinine or a pharmaceutically acceptable salt thereof, which amount is effective to reduce or alleviate at least one of the symptoms of schizophrenia, Tourette's Syndrome, obsessive-compulsive disorder, substance abuse or substance addiction including drug or alcohol addiction, manic-depression syndrome, anexoria or bulimia in a human or other mammal.

Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

1. A method of treating a patient suffering from obsessive-compulsive disorder, said method comprising,

providing for such a patient a pharmaceutical agent comprising cotinine or a pharmaceutically acceptable salt thereof in a dosage between about 0.5 mg/kg to 100 mg/kg body weight per day for alleviating, in a human in need of such treatment, at least one of the symptoms of obsessive-compulsive disorder.

2. The method of claim 1 wherein the pharmaceutical agent or said salt is selected from the group consisting of a tablet or capsule, a transdermal delivery system, a chewing gum, an interocular insert, an inhaler and an aqueous solution of cotinine.

3. A method of treating a patient suffering from Tourette's Syndrome, said method comprising,

providing for such a patient a pharmaceutical agent comprising cotinine or a pharmaceutically acceptable salt thereof in a dosage between about 0.5 mg/kg to 100 mg/kg body weight per day for alleviating, in a human in need of such treatment, at least one of the symptoms of Tourette's Syndrome.

4. The method of claim 3 wherein said pharmaceutical agent or said salt is selected from the group consisting of a tablet or capsule, a transdermal delivery system, a chewing gum, an interocular insert, an inhaler and an aqueous solution of cotinine.

5. A method of treating a patient suffering schizophrenia, said method comprising,

providing for such a patient a pharmaceutical agent comprising cotinine or a pharmaceutically acceptable salt thereof in a dosage between about 0.5 mg/kg to 100 mg/kg body weight per day for alleviating, in a human in need of such treatment, at least one of the symptoms of schizophrenia.

6. The method of claim 5 wherein the pharmaceutical agent or said salt is selected from the group consisting of a tablet or capsule, a transdermal delivery system, a chewing gum, an interocular insert, an inhaler and an aqueous solution of cotinine.

7. A method of treating a patient suffering from substance abuse or substance addiction, said method comprising,

providing for such a patient a pharmaceutical agent comprising cotinine or a pharmaceutically acceptable salt thereof in a dosage between about 0.5 mg/kg to 100 mg/kg body weight per day for alleviating, in a human in need of such treatment, at least one of the symptoms of substance abuse or substance addiction.

8. The method of claim 7 wherein the pharmaceutical agent or said salt is selected from the group consisting of a tablet or capsule, a transdermal delivery system, a chewing gum, an interocular insert, an inhaler and an aqueous solution of cotinine.

9. The method of claim 7 wherein the addiction comprises drug or alcohol addiction.

10. The method of claim 9 wherein the pharmaceutical agent or said salt is selected from the group consisting of a tablet or capsule, a transdermal delivery system, a chewing gum, an interocular insert, an inhaler and an aqueous solution of cotinine.

11. A method of treating a patient suffering from manic-depression syndrome, said method comprising,

providing for such a patient a pharmaceutical agent comprising cotinine or a pharmaceutically acceptable salt thereof in a dosage between about 0.5 mg/kg to 100 mg/kg body weight per day for alleviating, in a human in need of such treatment, at least one of the symptoms of manic-depression syndrome.

12. The method of claim 11 wherein the pharmaceutical agent or said salt is selected from the group consisting of a tablet or capsule, a transdermal delivery system, a chewing gum, an interocular insert, an inhaler and an aqueous solution of cotinine.

13. A method of treating a patient suffering from anorexia or bulimia, said method comprising,

providing for such a patient a pharmaceutical agent comprising cotinine or a pharmaceutically acceptable salt thereof in a dosage between about 0.5 mg/kg to 100 mg/kg body weight per day for alleviating, in a human in need of such treatment, at least one of the symptoms of anorexia or bulimia.

14. The method of claim 13 wherein the pharmaceutical agent or said salt is selected from the group consisting of a tablet or capsule, a transdermal delivery system, a chewing gum, an interocular insert, an inhaler and an aqueous solution of cotinine.

Referenced Cited
U.S. Patent Documents
3870794 March 1975 Hutchinson et al.
4946853 August 7, 1990 Bannon et al.
5187169 February 16, 1993 Lippiello et al.
5298257 March 29, 1994 Bannon et al.
5596007 January 21, 1997 Keenan et al.
5612357 March 18, 1997 Keenan et al.
5643928 July 1, 1997 Keenan et al.
Foreign Patent Documents
273715 August 1962 AUX
Other references
  • Freedman R., Hall M., Adler LE, Leonard S. "Evidence of Postmortem Brain Tissue for Decreased Numbers of Hippocampal Nicotinic Receptors in Schizophrenia", Biol. Psychiatry, 38(1):22-33 (1995). Newhouse, P.A., Potter A., Corwin J., Lenox R., "Age-related Effects of the Nicotinic Antagonist Mecamylamine on Cognition and Behavior", Neuropsychopharmacology, 10(2): 93-107 (1994). McConville B.J., Sanberg P.R., Fogelson M.H., et al. "The Effects of Nicotine Plus Haloperidol Compared to Nicotine Only and Placebo Nicotine Only in Reducing Tic Severity and Frequency in Tourette's Disorder", Biol. Psychiatry 31(8): 832-840 (1992). Rosecrans JA. "The Role of Nicotine in Tobacco Dependence and Cessation", Chemistry and Industry, pp. 221-224 (Mar. 21, 1994).
Patent History
Patent number: 5889029
Type: Grant
Filed: Nov 13, 1997
Date of Patent: Mar 30, 1999
Assignee: LecTec Corporation (Minnetonka, MN)
Inventor: David Rolf (Eden Prairie, MN)
Primary Examiner: Phyllis G. Spivack
Attorney: James V. Harmon
Application Number: 8/969,767
Classifications
Current U.S. Class: The Additional Hetero Ring Consists Of One Nitrogen And Four Carbons (e.g., Nicotine, Etc.) (514/343)
International Classification: A61K 31465;